ARASTEP

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 23, 2023 → Aug 4, 2026

Cited window

Jan 26, 2024 → Jan 9, 2026

Retrieved

Oct 31, 2026

Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer

Registry

NCT05794906

Study IDs

21492 · 2022-501343-33-00 (CTIS (EU))

Sponsor

Bayer

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

985 actual

Registered

2023-04-03

Start

2023-04-03 actual

Primary completion

2027-07-30 estimated

Primary endpoint

Radiological progression-free survival (rPFS) by Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) assessed by Blinded independent central review (BICR)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a question about individualizing novel antiandrogen selection according to cardiac and neurological risk.
• –Not yet captured in this edition: a view on individualized anti-androgen selection, practical ease of use, and patient discussion of benefits and adverse effects.
• –Not yet captured in this edition: a view on treatment benefits, survival expectations and comparative toxicities of systemic options for high-risk biochemical recurrence.
• –Not yet captured in this edition: a view on efficacy, survival qualifications and comparative toxicity when choosing systemic treatment for high-risk biochemical recurrence.
• –Not yet captured in this edition: a view on toxicity-driven ADT interruption and combination treatment versus selective monotherapy in biochemical recurrence.
• –Not yet captured in this edition: a view on toxicity-driven ADT interruption and hormonal monotherapy versus combination treatment in biochemical recurrence.
• –Not yet captured in this edition: a remark on attribution of relayed commentary about trial design and potential practice change in biochemical recurrence.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are selective and do not establish the prevalence of any opinion among HCPs. Reposts, relayed discussions and repeated podcast/video formats are not independent clinical endorsements.
• –Some connected treatment-selection remarks are missing. Several social-media passages and parts of recorded discussions were not fully assessed, so additional views and consequential qualifications may be absent.
• –Discussion that does not name ARASTEP, or uses an unrecognized spoken variant, may be missing. Coverage of the clinical question is therefore not exhaustive.
• –Not every named contributor has a documented clinical role. A profile's stated specialty or credential is not independent confirmation, and dated practice associations do not establish current employment.
• –Unidentified recorded passages cannot be assigned to named participants from a program title, participant list or similar voice label.
• –Presenting and steering-committee involvement are descriptions made by the sources; they do not independently validate a view or increase its evidentiary weight.
• –The sources provide trial methods and prospective expectations, not ARASTEP efficacy or safety results. Observational signals, historical comparisons and estimates must not be substituted for its pending randomized answer.
• –The methods context comes from registry information and a protocol publication rather than a separately listed full protocol document. No exact regulatory label was available to establish an approved indication for this regimen.
• –Posting and publication dates locate statements, not trial readouts or changes of mind. Differences across cases and treatment settings should not automatically be called disagreement.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ARASTEP" (NCT05794906), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "arastep-05794906". If you cannot make requests, read https://www.erudio.com/reports/arastep-nct05794906.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05794906", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05794906 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/arastep-nct05794906.json
curl https://www.erudio.com/reports/arastep-nct05794906.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "arastep-05794906" })